

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Purified anti-human CD45

RRID:AB_314390

Type: Antibody

Proper Citation

BioLegend Cat# 304002, RRID:AB_314390

Antibody Information

URL: http://antibodyregistry.org/AB_314390

Proper Citation: BioLegend Cat# 304002, RRID:AB_314390

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF®, IHC-P, WB, IHC-F, ICC

Antibody Name: Purified anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_314390

Vendor: BioLegend

Catalog Number: 304002

Alternative Catalog Numbers: 304001

Record Creation Time: 20250819T213723+0000

Record Last Update: 20250819T233349+0000

Ratings and Alerts

- Used for cytometry time of flight assay by the Human Islet Research Network community. Contact(s): [Bernd Bodenmiller](mailto:Bernd.Bodenmiller@hirnetwork.org) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Purified anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Yang Z, et al. (2026) Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. *Cell reports. Medicine*, 7(2), 102613.

Babdor J, et al. (2026) Immune-microbiome coordination defines interferon setpoints in healthy humans. *Cell*, 189(10), 3144.

Horbach N, et al. (2025) Visualization of calpain-1 activation during cell death and its role in GSDMD cleavage using chemical probes. *Cell chemical biology*, 32(4), 603.

Xu J, et al. (2025) Minimally invasive diagnosis of precancerous cervical lesions using single-cell peripheral immune atlas. *Cell reports. Medicine*, 6(6), 102149.

Stankiewicz LN, et al. (2025) Sex-biased human thymic architecture guides T cell development through spatially defined niches. *Developmental cell*, 60(1), 152.

Simoni-Nieves A, et al. (2024) A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib. *Cell reports. Medicine*, 5(9), 101703.

Chauhan SK, et al. (2024) Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation. *NPJ breast cancer*, 10(1), 30.

Kong XX, et al. (2024) Circulation immune cell landscape in canonical pathogenesis of colorectal adenocarcinoma by CyTOF analysis. *iScience*, 27(3), 109229.

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. *Cancer cell*, 42(1), 35.

Loh L, et al. (2024) Unraveling the phenotypic states of human innate-like T cells: Comparative insights with conventional T cells and mouse models. *Cell reports*, 43(9), 114705.

Zhu Y, et al. (2023) Opioid-induced fragile-like regulatory T cells contribute to withdrawal. *Cell*, 186(3), 591.

Xu Y, et al. (2023) CD16⁺ monocytes are involved in the hyper-inflammatory state of Prader-Willi Syndrome by single-cell transcriptomic analysis. *Frontiers in immunology*, 14, 1153730.

Zhang Z, et al. (2023) Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma. *Med (New York, N.Y.)*, 4(10), 728.

Yu S, et al. (2023) Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine. *Cell*, 186(21), 4615.

Schmidt F, et al. (2023) In-depth analysis of human virus-specific CD8⁺ T cells delineates unique phenotypic signatures for T cell specificity prediction. *Cell reports*, 42(10), 113250.

Trobisch T, et al. (2022) Cross-regional homeostatic and reactive glial signatures in multiple sclerosis. *Acta neuropathologica*, 144(5), 987.

De Vargas Roditi L, et al. (2022) Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. *Cell reports. Medicine*, 3(4), 100604.

Feyaerts D, et al. (2022) Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. *Cell reports. Medicine*, 3(7), 100680.

Alpert A, et al. (2022) Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples. *Cell systems*, 13(1), 71.

Schwabenland M, et al. (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. *Immunity*, 54(7), 1594.